The CSF p-tau181/A β42 Ratio Offers a Good Accuracy "in Vivo" in the Differential Diagnosis of Alzheimer's Dementia.

CONCLUSIONS: The p-tau181/Aβ42 ratio alone might reliably detect AD pathology in heterogeneous samples of patients suffering from different types of dementia. It might constitute a simple, cost- effective and reproducible in vivo proxy of AD suitable to be adopted worldwide not only in daily clinical practice but also in future experimental trials, to avoid enrolment of misdiagnosed AD patients.
PMID: 31345148 [PubMed - as supplied by publisher]

Source: Current Alzheimer Research - July 24, 2019 Category: Neurology Authors: Santangelo R, Dell Edera A, Sala A, Cecchetti G, Masserini F, Caso F, Pinto P, Leocani L, Falautano M, Passerini G, Martinelli V, Comi G, Perani D, Magnani G Tags: Curr Alzheimer Res Source Type: research